Introduction
There are three major types of cardiomyopathy: hypertrophic (HCM), dilated (DCM), and restrictive (RCM), with RCM being the least common and ultimately the least studied. 1 RCM is a heterogeneous disorder that can present with a spectrum of cardiac phenotypes including HCM in family members. [2] [3] [4] The prognosis for RCM has been poor and some patients die in childhood. 5 RCM is characterized by increased stiffness of the left ventricular (LV) wall with no increase in wall thickness and a largely impaired diastolic function with usually normal or near-normal systolic function. 3 RCM is rare in children, but the prognosis is poor and the risk for ischemia-related complications and death is high. 6 RCM has been associated with several mutations in sarcomeric proteins, including troponin-I (TnI), troponin-T (TnT), actin, myosin binding protein C and b-myosin heavy chain (b-MHC). 7, 8 In this study, we report on the first myosin essential light chain (ELC) mutation, E143K, where glutamic acid (E) is mutated to lysine (K), reported to result in HCM of restrictive physiology in humans. 9, 10 In the first report, the mutation was discovered in a young male proband, homozygous for E143K during his medical evaluation due to the pre-mature death of his two younger siblings. 10 Another incidence of early death, at 7 years of age, was also reported in distant branch of the family. All family members homozygous for E143K manifested severe HCM in childhood. 10 In the second study, E143K was found in a 22 year-old female proband diagnosed with RCM and class III/IV heart failure while awaiting heart transplantation. 9 Transthoracic echocardiogram evaluation of the proband revealed a severe biatrial enlargement with preserved biventricular systolic function and no LV hypertrophy, while the Doppler interrogation indicated advanced LV diastolic dysfunction. 9 The lack of LV hypertrophy was paralleled by elevated right-sided and left-sided filling pressures and interstitial fibrosis.
To address the mechanism underlying the development of ELC-RCM phenotype, we generated transgenic (Tg) mice expressing the E143K-mutated human ventricular myosin ELC, the first animal model of human RCM with a mutation in myosin light chains, and the first RCM Tg murine model with a mutation in the thick filaments. Despite $55% of E143K expression, we were able to recapitulate the major aspects of the human phenotype, whereas E143K-positive patients displayed the RCM symptoms only when both alleles were mutated. 10 Male (M) and female (F) E143K mice manifested diastolic disturbance, especially in senescent animals, with ultrastructural cardiac defects and fibrosis that most likely contributed to mild systolic dysfunction. At the level of myosin molecules, a hypercontractile E143K-phenotype was observed evidenced by enhanced binding of myosin to actin in rigor, elevated actin-activated myosin ATPase activity and E143K-induced increase in the myosin duty ratio. Importantly, myosin RLC phosphorylation, shown to be critical for the normal function of the heart, was reduced in E143K-ELC mice. Finally, proteomic investigations revealed significant alterations in the metabolic processes involving ATP production and changes in the expression of energy related mitochondrial proteins.
Methods
This study conforms to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication no. 85-23, revised 2011). All protocols were approved by the Institutional Animal Care and Use Committee at the University of Miami Miller School of Medicine. The assurance number is #A-3224-01, effective November 24, 2015. Euthanasia of mice was achieved through inhalation of CO 2 followed by cervical dislocation. The generation and characterization of Tg-mice expressing the human cardiac myosin ELC WT (NCBI accession number: P08590) used in this study was described earlier. [11] [12] [13] The same methodology was used to generate Tg-E143K mice (L1 and L2 expressing 0 and $55% transgene, respectively, and the results were compared with those obtained for Tg-WT L4 expressing 74% of human ventricular WT-ELC, as determined in cardiac myofibrils from three age groups (2-3, 5-6, and 10-11 mo-old) of mutant vs. WT-ELC mice (see Supplementary material online, Figure  S1 ). The paraffin-embedded longitudinal sections of whole mouse hearts, stained with haematoxylin and eosin and Masson's trichrome, were examined for overall morphology and fibrosis, and the myocardial ultrastructure was assessed by transmission electron microscopy as described earlier.
14 Hydroxyproline (HOP) content was determined using the HOP assay and the collagen and stress response gene profiles were assessed by real time qPCR.
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Cardiac morphology and function were examined in 5-6 and 11-12 mo-old male (M) and female (F) E143K and WT mice by echocardiography, invasive haemodynamics and muscle fibre mechanics studies. 11, 14 Steady-state force development, force-pCa relationship, passive tension and small-angle X-ray diffraction experiments on skinned papillary muscles were conducted as described earlier. 13, 14 Binding of E143K-mouse myosin to pyrene-actin, actin-activated myosin ATPase activity and stopped-flow kinetics were performed as previously reported.
11,13
In vitro motility and Qdot assays, followed by simulations of data ensembles, were conducted as outlined earlier. [15] [16] [17] Proteomics experiments on the hearts from E143K vs. WT mice were carried out according to Gomes et al.
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All values are shown as means ± SEM (standard error of the mean). Statistically significant differences between two groups were determined using an unpaired Student's t-test, with significance defined as *P < 0.05 and **P < 0.01. Comparisons between multiple groups were performed using one-or two-way ANOVA. Statistical procedures of the motility and Qdot assays and proteomic experiments are described in the Supplementary material online.
Details of materials and experimental procedures are in the Methods in the Online Data Supplement.
Results
This report focuses on the mechanisms by which the first RCM-linked mutation in myosin ELC regulates the development of RCM in mice. Using the cardiac specific a-MHC promoter, 11, 12 E143K-L1 and E143K-L2 mice were produced expressing 0 and $55%, respectively, of the human ventricular ELC-E143K mutant protein in the hearts of mice.
Western blots analysis performed on cardiac myofibrils from left ventricles of 2-3, 5-6, and 10-11 mo-old E143K-L2-mice and probed with monoclonal ELC-specific antibody (ab680, Abcam) is presented in Supplementary material online, Figure S1 . A slightly lower expression was observed in the youngest E143K mice ($51%) but no differences were noted between 5-6 ($58%) and 10-11 ($56%) mo-old E143K-mice. No differences in any age group were observed between male and female mice. The results obtained for E143K-L2 animals were compared with age and gender matched WT mice, 11 expressing $74% of the human ventricular ELC (see Supplementary material online, Figure S1 ).
RCM-linked myosin ELC model mice

LV fibrosis and ultrastructural defects in E143K-hearts
Histopathological evaluation of 5-6 mo-old and 11-12 mo-old E143K animals showed mild fibrosis in the hearts of younger group of mice of both genders, but severe fibrotic lesions in older mutant hearts compared with respective WT controls ( Figure 1A ). Myocardial ultrastructure assessed by transmission EM revealed significant sarcomere irregularities with Z-lines streaming and M-lines vanishing in $11 mo-old E143K-mice compared with WT hearts ( Figure 1B) . In support of histopathology findings, a significant increase in HOP content was measured in the hearts of $11 mo-old E143K vs. WT mice by HOP assay: 18.46 ± 1.22 vs. 15.09 ± 0.43 lM/mg (t-test, *P < 0.05) ( Figure 1C) . Occurrences of fibrosis in E143K-hearts were confirmed by real-time PCR, showing upregulation of collagen type-I and III and a stress response gene, ANF, in $6 mo-old E143K mice compared with age-matched WT-controls. Additionally, a-MHC (Myh6 gene) was significantly downregulated in E143K hearts compared with WT hearts ( Figure 1C ). Downregulation of a-MHC observed in E143K mice did not coincide with increased b-MHC protein expression in E143K vs. WT mice (see Supplementary material online, Figure S2) ; however, the possibility exists that the relative content of b-MHC in total MHC was increased in E143K hearts.
Diastolic dysfunction without LV hypertrophy in E143K mice
The in vivo consequences associated with E143K-ELC were assessed by echocardiography and invasive haemodynamics performed on 5-6 and 11-12 mo-old E143K vs. WT mice of both genders. Consistent with the RCM phenotype with preserved systolic function, 3, 5 no differences were noted in the ejection fraction (EF in %) and fractional shortening (FS in %) in the young and old E143K vs. WT mice (Figures 2-3 , see Supplementary material online, Tables S1 and S2). The hearts of E143K animals did not show any hypertrophic growth compared with age matched controls, and on the contrary, the heart weight-to-body weight ratio was significantly lower in 5-6 mo-old E143K mice of both genders ( Figure 2A , see Supplementary material online, Table S1 ) and in 11-12 mo-old E143K-M mice ( Figure 3A , see Supplementary material online, Table S2 ) compared with respective WT controls. Additionally, LV inner diameters (LVID) in diastole and systole were smaller in young and old E143K-M than in WT-M mice indicating a more pronounced RCM phenotype in male vs. female mutant mice. Haemodynamic evaluation showed a significant decrease in stroke volume (SV) with a decline in LV end-diastolic volume (EDV) and reduced cardiac output (CO) in 5-6 mo-old E143K-M mice, while female counterparts showed a significant increase in the relaxation time, Tau compared with respective WT controls ( Figure 2B) . The values of the peak rate of LV relaxation (-dP/dt min ) were lower in M and F E143K animals compared with age and gender matched WT mice and although the differences did not reach statistical significance, the trend of changes in E143K animals was suggestive of diastolic disturbance ( Figure 2B , see Supplementary material online, Table S1 ). These data indicated that 5-6 mo-old E143K mice of both genders were pre-disposed to diastolic dysfunction.
Evaluation of 11-12 mo-old mutant vs. WT mice revealed a more pronounced phenotype in male vs. female E143K compared with WT mice (Figure 3 , see Supplementary material online, Table S2 ), a trend also observed in other animal models of heart disease. 19 The mitral valve Doppler assessment showed a significant increase in the isovolumetric relaxation time (IVRT) in E143K-M mice compared with WT-M animals.
However, the diastolic indices, end-diastolic pressure (EDP), Tau and EDPVR were significantly altered (higher) in 11-12 mo-old E143K mice of both genders compared with age and gender matched WT animals, showing a pre-disposition of old E143K-mice to diastolic dysfunction ( Figure 3B , see Supplementary material online, Table S2 ). The systolic indices, CO, SV, ESV, and EDV were significantly reduced in older E143K-M compared with WT-M mice, but female mice showed a significant reduction in stroke work (SW) compared with age matched WT-F animals. In addition, ESPVR (slope of the end-systolic PV relation) in E143K-M mice and PRSW (pre-load recruited SW-slope of the SW-EDV relationship) in E143K-F mice were significantly lower compared with respective WT controls, indicating impairment of systolic function in old mutant animals ( Figure 3B , see Supplementary material online, Table S2 ).
Although the pre-dominant phenotype observed in M and F senescent E143K animals was diastolic dysfunction, the mutation also resulted in a mild systolic disturbance compared with age and gender matched WT controls.
Hypercontractility and increased ventricular stiffness in E143K-skinned fibers
Papillary muscle strips were isolated from 5 to 6 mo-old and 11 to 12 mo-old mice, dissected to $1.5 mm in length and $100 lm in diameter, attached to a Guth force transducer and the sarcomere length was adjusted to 2.1 mm. 20 After maximal force determination in pCa 4 solution, the strips were exposed to solutions of increasing concentration of Ca 2þ (pCa 8-4) and the force-[Ca 2þ ] relationship was established (see Figure 4A , significantly increased maximal force was observed for fibres from 5 to 6 mo-old E143K-M and 11 to 12 mo-old E143K-F/M mice compared with respective WT mice, but only E143K-M mice demonstrated a small increase in the Ca 2þ -sensitivity of force. Therefore, consistent with the in vivo evaluation, a more pronounced RCM phenotype was observed in skinned muscle fibres from male vs. female mutant mice ( Figure 4B ). It is important to note that fibrosis and ultrastructural defects observed in LV walls of $11 mo-old E143K hearts ( Figure 1A , B) were most likely absent in the papillary muscles of E143K mice that were used for functional mechanical measurements. As we demonstrated previously, 21 LV papillary muscles of 2, 3, and 12.5 mo-old HCM mice maintained normal morphology, with no obvious myofibrillar disarray and interstitial fibrosis that we found abundant in LV and IVS compartments of mutant animals 21 and observed in E143K mice ( Figure 1A , B). Thus, increased tension measured in E143K papillary muscles was most likely due to the hypercontractile activity of myosin motor and was not affected by sarcomere damage in old E143K mice. The ability of myosin to generate force in E143K mice correlated with the results from small angle X-ray diffraction studies showing significantly reduced interfilament lattice spacing (d 1,0 ) measured under relaxation conditions in E143K-fibers compared with WT ( Figure 4C ). Consistent with this result, the level of passive tension (at pCa 8) in response to muscle stretch was significantly increased in E143K vs. WT mice ( Figure 4D ). Therefore, in agreement with functional assessments of E143K-hearts, abnormal muscle stiffness was observed in our RCM-ELC mouse model.
Supplementary material online, for details). As shown in
Enhanced interaction of mutant-myosin with actin
Binding of E143K vs. WT myosin to pyrene-F-actin under rigor conditions (no ATP) showed two different profiles for the mutant and WT myosin and a higher affinity of E143K-myosin to pyrene-actin ( Figure 5A) . Consistent with the hypercontractile mutant-myosin performance, the actin-activated myosin ATPase activity was higher for E143K compared with WT myosin ( Figure 5B ). The higher V max indicated a faster transition from the weakly to strongly bound cross-bridges, with phosphate release being rate-limiting 22 in the mutant vs. WT myosin ( Figure 5B) , suggesting a mutation induced increase in the myosin duty ratio. 23 The
Michaelis-Menten constant for E143K myosin was not different from WT (K m = 1.14 ± 0.10 vs. 1.19 ± 0.12 lM). To further demonstrate the effect of E143K on interaction of myosin with actin, the MgATPdependent transition from strongly (AÁM) to weakly (AÁMÁATP) bound acto-myosin complex was measured using pyrene-F-actin. E143K and WT myosins were stoichiometrically mixed with pyrene-F-actin and the complexes were mixed in a 1:1 (vol/vol) ratio with increasing Figure 5C ). Individual acto-myosin dissociation rates, k obs , for different ATP concentrations were also smaller in E143K myosin compared with WT ( Figure 5D ). A decrease in the rate of dissociation of acto-myosin complex by MgATP observed in E143K hearts could also be due to the downregulation of a-MHC ( Figure 1C) , thereby increased ratio of b-MHC/a-MHC in total MHC content of E143K hearts. Altogether, these data indicate that in the absence of nucleotide, E143K-ELC myosin elicits significantly stronger interactions with actin than WT myosin and decreases the rates of ATP dependent relaxation of the acto-myosin complex. 
In vitro motility and Qdot study
V max and K m Michaelis-Menten parameters obtained at low ionic strength imitating in vitro motility conditions are summarized in Supplementary material online, Table S3 . V max increased two-fold for E143K over WT paralleling the trend at higher ionic strength ( Figure 5B ). In vitro motility velocity, v m , saturated at $0.1 lM myosin bulk concentration and converged to similar maximum velocities for WT and E143K-myosins. Maximum motility velocities are likewise summarized in Supplementary material online, Table S3 . 
motility velocity v m , and V max in the expression <f> = V max <d>/v m . Results indicated a two-fold increase in duty ratio for E143K due to two-fold increase in V max coupled with modest and compensating changes to <d> and v m for the mutant compared with WT. These data are consistent with enhanced force production for heart tissues containing the mutant motor.
Data in Figure 6 indicate that the mouse cardiac myosin moves actin with three unitary step-sizes. Actin binding of the ELC N-terminus plays a central role in the mechanism for generating the short and long myosin step-sizes. 16, 24 As shown, E143K mutation reduces step-size in the short and long steps implicating the ELC N-terminus actin binding interaction. 
Metabolic and structural changes and protein phosphorylation in E143K vs. WT hearts
To understand the signalling triggers of RCM in E143K mice and capture relatively early changes in the metabolic/structural makeup of E143K vs. WT hearts, 3.6 mo-old F mice from both groups were subjected to an in-depth proteomic analysis. The reason that female mice have been chosen were recent studies showing that in all cardiomyopathy subtypes, there was an unequal sex distribution, with a tendency towards men for HCM and DCM, and towards women for RCM. 25 Reports also showed that under disease conditions, females have higher expression of genes related to energy metabolism and can better maintain their metabolic function in response to a disease stimulus than males. 26 The data revealed that out of 758 identified proteins, 43 were differently expressed between E143K and WT mice ( Figure 7A , see Supplementary material online, Table S4 ). The majority of upregulated proteins in E143K hearts was involved in ATP production and in mitochondrial metabolism. Consistent with a fatty acid to glucose metabolism pathway shift under stress or pathological conditions, 27, 28 hexokinase-1,2 (G3UVV4, HXK2) proteins, responsible for glucose metabolism and the glycolytic ATP production pathway, were upregulated in E143K. Upstream of the b-oxidation of fatty acid (FA), acyl coenzyme A synthetase1 (ACSL1) and carnitine O-palmitoyltransferase 1 (CPT1b), that are responsible for activation and translocation of FA into mitochondria, [29] [30] [31] were upregulated in E143K-animals. In addition, carnitine O-acetyltransferase (CACP), responsible for transporting acetylcarnitine out of the mitochondria and inhibiting FA oxidation, 32 was also upregulated in E143K-mice ( Figure 7B ). Several mitochondrial membrane proteins, including complex I (NADH dehydrogenase) subunits (NADUS2, NADUA9, NSUAA and NDUS1), 33 which are responsible for the electron transport and proton gradient across the membrane for ATP production, 34 were upregulated in E143K-mice. Fatty acid transport metabolites (CPT1b, CACP) and the voltage dependent anion channel (VDAC1), involved in the transport of anions, cations and metabolites across the outer membrane of mitochondria, 35, 36 were all upregulated in the mutant mice. Upregulation of VDAC1 was confirmed by western blot performed on LV samples from E143K vs. WT ( Figure 7C, D) . Based upon the resolution of quantitative proteomics that was used in this study, the E143K elicited changes, although small, are likely to be biologically important and may underlie the molecular signatures of RCM-ELC hearts. Interestingly, sarcomeric proteins such as cardiac TnI, TnT, ventricular myosin regulatory light chain (RLC) and a-MHC were downregulated while desmin was upregulated in the RCM model compared with WT Table S4 ). Downregulation of a-MHC was confirmed by real-time qPCR ( Figure 1C) . We also tested the effect of E143K on phosphorylation of cardiac TnI and myosin RLC (see Supplementary material online, Figure S3 ). The data were acquired using cardiac myofibrils isolated from three-age groups (2-3, 5-6, and 10-11 mo-old, females and males) of E143K vs. WT mice. A significantly lower RLC phosphorylation was observed in 2-3 mo-old and 5-6 moold E143K compared with WT animals (see Supplementary material online, Figure S3 ). Decreased phosphorylation in 10-11 mo-old E143K vs. WT mice did not reach statistical significance. At the same time, no changes in TnI phosphorylation was observed. One has to note that small increases in maximal tension and calcium sensitivity of force observed in E143K papillary fibers (Figure 4) would likely have been larger in the absence of counteracting activity of the poorly phosphorylated RLC.
Collectively, our results demonstrate that a charge modification (glutamic acid ! lysine) on the ELC significantly changes the intermolecular interactions between ELC and the myosin heavy chain and between the myosin cross-bridges and actin and triggers an abnormal ability of myosin to generate the power stroke and muscle contraction. This hypercontractile activity of myosin ultimately leads to abnormalities in cardiac systolic and diastolic function and morphology, and induces metabolic reprogramming in the E143K hearts.
Discussion
Genetic mutations in cardiac myosin light chains (ELC and RLC) are known to cause familial HCM with asymmetric septal hypertrophy and frequent occurrences of sudden cardiac death. 37 Several HCMlinked ELC mutations were studied in Tg mice, 11, 38 but this study is the first to address the molecular mechanism of E143K-induced RCM in mice and the degree to which the phenotype resembles that observed in E143K-positive patients. 9, 10 Our data indicate that despite $55% incorporation of E143K into the hearts of mice, we were able to recapitulate the major aspects of human RCM (e.g. diastolic disturbance, interstitial fibrosis), whose pronounced phenotype could only be observed in homozygous E143K-patients. 10 Male and female mutant mice manifested mildly altered morphology and function at 5-6 months of age and significantly progressed to severely defective morphology at 11-12 months. Throughout the life, the hearts of mutant-animals have not hypertrophied and with the Figure 6 Stepping patterns of myosin motors in E143K and WT mice. Qdot motility assay was used to measure step-size and step-frequency exception of older E143K-F, the hearts of F and M E143K-mice became significantly smaller compared with age and gender matched WT mice. It is important to note that male (young and old) E143K-mice showed more evidence of disease than their female counterparts, a phenomenon also observed in other models of genetic cardiomyopathy. 19, 26 In humans, gender differences are clearly observed at every level of cardiovascular physiology from action potential duration, mitochondrial energetics to isolated muscle fibre and whole-heart contractile function. 19 As observed in our study with 5-6 mo-old female E143K mice showing mild detrimental cardiac changes compared with age matched male counterparts and to senescent F and M mice, studies in humans RCM-linked myosin ELC model mice revealed that cardioprotection, that is present in younger women, is generally lost later in life, suggesting a role for estrogen in cardiovascular biology. In animal studies, estrogen was shown to protect from Ang IIinduced hypertrophy in ovariectomized mice supplemented with estrogen during Ang II treatment. 39 This protection in female mice, however, was lost with depletion of endogenous sex hormones. Consistent with our results, significant sex differences were also found in a mouse model of TAC showing a more pronounced increase in myocardial hypertrophy and fibrosis in male animals. 26 Interestingly, treatment with E2, a major circulating estrogen, has been shown to inhibit LV hypertrophy and prohypertrophic gene expression in the TAC model. 40 These reports suggest that females E143K mice may be protected against effects of RCM and thus demonstrate a milder phenotype of disease that males (Figures 2-4) . Cardiac fibrosis is a hallmark of HCM that largely contributes to arrhythmias and heart failure and evidence is accumulating for increased ratios of collagen synthesis to degradation in HCM patients. 41 Studies on humans and animal models indicate that profibrotic gene pathways can be activated much earlier than hypertrophic cardiac remodelling, and increased myocardial collagen synthesis was observed in sarcomere mutation carriers prior to the development of LV hypertrophy and fibrosis. 41 Consistent with these reports, 5-6 mo-old E143K-mice showed mild fibrosis while collagen type I and III genes were upregulated ( Figure  1A , C). Therefore, in addition to symptom-based treatments of RCM patients with diuretics to decrease filling pressures, beta-blockers and angiotensin-converting enzyme (ACE) inhibitors, the synthesis of collagen has been targeted. 5 In fact, many of the beta-blockers and ACE inhibitors (e.g. valsartan) were shown to suppress the synthesis of type I collagen in patients with HCM. 42 Altogether, these treatments of RCM and anti-fibrosis in particular hold promise in that cardiac transplantation, despite currently being the most effective procedure in treating RCM, 5 is not a sole solution to the problem. Studies in E143K papillary muscle fibers, that are pre-dominantly free of fibrotic depositions, 21 showed an increased ability of myosin to generate maximal force supporting the idea of E143K-induced pathological hypercontractile state of myosin motor ( Figure 4A) . Likewise, E143K myosin showed a higher affinity for actin under rigor conditions which, when placed in vivo, could contribute to increased LV stiffness and cause abnormal resistance to ventricular filling and diastolic disturbance. The hypercontractility-like state observed in E143K mice was also evident in acto-myosin interaction with significantly higher actin-activated ATPase activity and increased myosin duty ratio measured in E143K vs. WT preparations. Consistent with these data, the rates of ATP-dependent dissociation of the acto-myosin complex were slower in E143K compared with WT mice, indicating a slower transition from the strongly to weakly bound myosin cross-bridges ( Figure 5) . Accordingly, single molecule studies demonstrated a large increase in the duty ratio for E143K vs. WT myosin, supporting the hypercontractile E143K-phenotype (see Supplementary material online, Table S3 ). Augmented maximal tension could also be due to increased muscle stiffness that would result in impaired muscle relaxation and ultimately in diastolic dysfunction. In line with this, X-ray measurements revealed a significant decrease in the lattice spacing in E143K vs. WT fibers under relaxation conditions (pCa 8) ( Figure 4C ). Reduced d 1,0 may indicate that the E143K-thick filaments become closer to the thin filaments facilitating the interaction of myosin with actin and promoting generation of force. Likewise, passive tension measured under relaxation conditions was increased in the mutant vs. WT mice, and this change is expected to contribute to increased stiffness in E143K myocardium ( Figure 4D ).
Our data on phosphorylation of cardiac TnI and myosin RLC, acquired in myofibrils from 2 to 3, 5 to 6, and 10 to 11 mo-old E143K vs. WT mice, revealed a significantly reduced phosphorylation of RLC with no changes in TnI phosphorylation in the mutant (see Supplementary material online, Figure S3 ). Thus, it is possible that small increases in maximal tension and calcium sensitivity of force observed in E143K papillary fibers would have been larger in the absence of counteracting activity of the poorly phosphorylated RLC. There is a large body of evidence showing that reduced RLC phosphorylation may result in abnormal heart performance in mice 43, 44 and in men, 45 presumably through morphological and/or myofibrillar functional alterations (e.g. change in force, myofilament calcium sensitivity, ATPase activity, cross-bridge kinetics). Likewise, attenuation of RLC phosphorylation in cMLCK knock-out mice was demonstrated to cause ventricular hypertrophy, fibrosis, and DCM. 46 Consistent with these data, no increase in I 1,1 /I 1,0 ratio was observed in E143K fibers, the result which is in accord with minute changes in Ca 2þ -sensitivity of force ( Figure 4A-C) . Therefore, reduced RLC phosphorylation most likely contributes to E143K-RCM phenotype and may represent a novel target for drug therapy. 14, 23 Proteomic studies demonstrated a mutation-induced abnormal metabolic makeup in E143K vs. WT hearts with changes in the processes involving ATP production and expression of energy related mitochondrial proteins. Disruption of the metabolic function of the heart is known to lead to cardiac (diastolic and systolic) abnormalities and development of cardiomyopathy, 47 and our data are in line with those showing the transition from a fatty acid metabolism to glucose metabolism pathway in the heart subjected to the pathologic stress. 27, 28 This pathological reprogramming of the E143K hearts was also evident by the upregulation of certain mitochondrial proteins including the ATP producing enzymes. Upregulation of several subunits of complex I, which plays a key role in cellular energy production by transferring electrons from NADH to ubiquinone, 33 were monitored in E143K vs. WT hearts. Most likely, the E143K mutated hearts with their abnormally stiff ventricles exhibit a high demand for ATP to sustain the hypercontractile myosin cross-bridge cycling (increased ATPase activity) leading to the pathological generation of force. Ultimately, metabolically compromised E143K hearts were unable to compensate for the abnormal energy demand resulting in more complex cardiac defects and systolic dysfunction as observed in older mutant hearts. Mechanistically, as a result of E143K-induced charge change on myosin ELC, the interaction of ELC with the myosin heavy chain and possibly with myosin RLC was significantly altered leading to changes in the steady-state and kinetics of acto-myosin interactions. These changes combined with alterations in sarcomeric protein phosphorylation and cellular accumulation of collagen resulted in structural and functional defects in E143K mice evidenced by stiffened ventricles and physiological, morphologic and metabolic remodelling consistent with the development of RCM in humans. This hypercontractility of myosin motor and its abnormal ability to generate the power stroke and muscle contraction is hypothesized to underlie the development of cardiac defects in E143K mice. Consistent with our data, modulation of force generation and stiffness of myosin motors by ELC and HCM-ELC mutations was recently shown by the Morano group. 38 Altogether, the experimental data suggest that our RCM-ELC mouse model may be highly suitable for testing of novel myosin specific therapeutics 23 aimed to normalize the myosin motor function, decrease pathological power production, and avert the hypercontractile state of the heart.
